NF
CLDX icon

NTB Financial’s Celldex Therapeutics CLDX Stock Holding History

NTB Financial’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-6,895
Closed -$235K – 144
2022
Q1 		$235K Hold
6,895
– – 0.17% 134
2021
Q4 		$266K Buy
+6,895
New +$300K 0.19% 121

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

NTB Financial's CLDX Position: Q2 2022 in Review

NTB Financial sold out of Celldex Therapeutics (CLDX) in Q2 2022, closing a stake of 6,895 shares — an estimated $235K sold.

NTB Financial first reported a position in CLDX in Q4 2021 and held it in 2 quarters. The position peaked at $266K in Q4 2021. 157 funds tracked by Wall St. Rank hold CLDX as of Q2 2022.

  • NTB Financial reported no remaining Celldex Therapeutics position as of Q2 2022 after selling out during the quarter.
  • NTB Financial sold 6,895 Celldex Therapeutics shares in Q2 2022, an estimated $235K.
  • NTB Financial first reported a position in Celldex Therapeutics in Q4 2021 and held it in 2 quarters.
  • NTB Financial's Celldex Therapeutics position peaked at $266K in Q4 2021.
  • 157 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2022.

Based on NTB Financial's 13F filing for Q2 2022, filed 9 Aug 2022.